Dr Ruchi Gupta provides AAAAI/WAO 2025 highlights, including anticipated presentations, quick takeaways, and insights into ...

The main signs of COVID-19 are respiratory symptoms, like congestion and a cough. But COVID-19 can also cause skin rashes, ...

Brrr! As temperatures drop, you might think all you need to worry about is bundling up, but did you know you could actually ...

A noteworthy case study. What caused a 43-year-old woman to develop lesions all over her body that were not only extremely ...

As temperatures drop, some individuals may experience an unusual allergic reaction to the cold, known as cold-induced ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of ...

Medically reviewed by Brendan Camp, MD Hives and eczema are two of the most common skin disorders. Hives, clinically known as ...

The FDA approval of SYMBRAVO for the acute treatment of migraines provides a significant new treatment option for millions of Americans suffering from this debilitating condition. SYMBRAVO ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).

It works by selectively blocking H1 histamine receptors, thereby preventing histamine from causing allergic symptoms such as itching, swelling, and hives that are characteristic ... a drug’s long-term ...

Management of urticaria de pends on its cause. Aggravating factors should be identified from the history, and triggering stimuli for physical urticaria avoided. Simple cooling lotions, as 0.5% to ...